| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-05-03 | Swedish Orphan Biovitrum - SOBI (Sweden) | new office in Athens | establishment of a new subsidiary in the EU | Rare diseases - Genetic diseases | Establishment of a new subsidiary in the EU | |
| 2017-05-03 | CARsgen Therapeutics (China) | CAR T-cell manufacturing facility in Shanghai | opening of new premises | Cancer - Oncology - Technology - Services | Opening of new premises | |
| 2017-05-03 | Gensight Biologics (France) | chief medical officer | nomination | Rare diseases - Genetic diseases - Ophtalmological diseases | Nomination | |
| 2017-05-03 | Rigontec (Germany) | chief medical officer | nomination | Cancer - Oncology | Nomination | |
| 2017-05-02 | Celyad (Belgium) Novartis (Switzerland) | licensing | Licensing agreement | |||
| 2017-05-02 | Verastem (US - MA) | nomination | Cancer - Oncology | Nomination | ||
| 2017-05-02 | Txcell (France) Inserm (France) | Chimeric Antigen Receptor (CAR) engineered CD8+Treg cells (CAR?Tregs) | R&D - research - licensing | Autoimmune diseases - Transplantation | Licensing agreement | |
| 2017-05-02 | Bluebird bio (USA - MA) GSK (UK) | lentiviral vector platform | Wiscott-Aldrich syndrome, metachromatic leukodystrophy | licensing - commercialisation | Rare diseases - Genetic diseases | Licensing agreement |
| 2017-05-02 | Bluebird bio (USA - MA) Novartis (Swtizerland) | lentiviral vector platform | licensing | Cancer - Oncology | Licensing agreement | |
| 2017-05-02 | Curevac (Germany) | nomination | Nomination | |||
| 2017-05-02 | Acceleron Pharma (USA - CA) | corporate advisor | nomination | Rare diseases - Genetic diseases - Neurological diseases | Nomination | |
| 2017-05-02 | Santhera Pharmaceuticals (Switzerland) Pharmathen (Greece) | Raxone® (idebenone) | Leber's hereditary optic neuropathy (LHON) | distribution - supply | Rare diseases - Genetic diseases - Ophtalmological diseases | Distribution agreement |
| 2017-05-02 | Neurovive Pharmaceutical (Sweden) Yungjin Pharm (South Korea) | KL1333 | genetic mitochondrial disorders | licensing | Rare diseases - Genetic diseases | Licensing agreement |
| 2017-05-01 | Shire (UK - USA) Parion Sciences (USA - NC) | P-321 | dry eye disease | licensing - development - commercialisation | Ophtalmological diseases | Licensing agreement |
| 2017-04-28 | Molmed (Italy) Megapharm (Israel) | Zalmoxis® - cell therapy product TK | adjunctive treatment in hematopoietic stem cell transplantation (HSCT) for patients affected by high risk leukaemia | licensing -commercialisation | Cancer - Oncology - Rare diseases - Transplantation | Commercialisation agreement |
| 2017-04-27 | Shire (UK - USA) | new office in Dublin | opening of new premises | Rare diseases - Genetic diseases - Hematological diseases | Opening of new premises | |
| 2017-04-27 | Agios Pharmaceuticals (USA -MA) Aurigene (India) | small molecule inhibitors of an undisclosed cancer metabolism target | licensing - research - development - commercialisation | Cancer - Oncology | Licensing agreement | |
| 2017-04-27 | Takeda Pharmaceutical (Japan) Harrington Discovery Institute (USA - OH) | research - R&D | Rare diseases | Research agreement | ||
| 2017-04-27 | Clovis Oncology (USA - CO) Myriad Genetics (USA - UT) | BRACAnalysis CDx for use with Rubraca® (rucaparib) | ovarian cancer | collaboration | Cancer - Oncology - Diagnostic | Collaboration agreement |
| 2017-04-26 | Lion Biotechnologies (USA - CA) Pharmacell (The Netherlands) | TIL (tumor infiltrating lymphocyte) products | manufacturing - production | Cancer - Oncology | Production agreement |
